COMMUNIQUÉS West-GlobeNewswire

Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential
09/01/2025
FMC-220 is a first-in-class covalent activator of p53 Y220C designed to address potency and tolerability challenges of non-covalent approaches In preclinical studies, FMC-220 demonstrated unprecedented potency and [...]
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
09/01/2025
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing [...]
Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference
09/01/2025
The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health series at this year’s conference to highlight the importance of innovation and growing [...]
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
09/01/2025
Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer’s Disease supports continued development of sabirnetug (ACU193) for treatment of early Alzheimer’s disease (AD) Sabirnetug demonstrated selective [...]
New England Life Care Selects Inovalon’s ScriptMed® to Scale Infusion Therapy and Specialty Pharmacy
09/01/2025
ScriptMed Infusion will Accelerate New England Life Care's Patient-Centric Care and Scale Pharmacy Operations BOWIE, Md., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Inovalon , a leading provider of cloud-based software solutions [...]
Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody Based Cancer Treatments from Oxford BioTherapeutics
09/01/2025
Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, today announced [...]
ElevateBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
09/01/2025
WALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering the creation of life-transforming genetic medicines, today announced that Chairman and [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
08/01/2025
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 08 janv. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Monthly information on share capital and company voting rights
08/01/2025
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results
08/01/2025
AUDUBON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year [...]
Lifeward Announces Closing of $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
08/01/2025
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what [...]
Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch
08/01/2025
-- Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients on LUMRYZ as of [...]
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences
08/01/2025
PURCHASE, N.Y., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced [...]
FluidForm Bio™ Announces Participation at Biotech Showcase and the 14th Annual LifeSci Partners Corporate Access Event
08/01/2025
WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced that Mike Graffeo, CEO and co-founder, will deliver a company [...]
NurExone Biologic Secures Master Cell Bank
08/01/2025
A Key Milestone for Therapeutic Exosome Production TORONTO and HAIFA, Israel, Jan. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (" NurExone " or the " Company "), a [...]
Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue
08/01/2025
Announces Earnings Release Date SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and [...]
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET
08/01/2025
WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living [...]
Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08/01/2025
SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation [...]
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
08/01/2025
Investigational new drug (IND) applications for initiating first-in-human studies for ZW220 and ZW251 in solid tumors anticipated in 2025 IND applications for initiating first-in-human studies for ZW209 and ZW1528 [...]

Pages